(b)(4).After receiving the ufr-mdr from fda, teleflex assembled a team and requested a meeting (b)(6) medical center (b)(6) 2019 at 1pm est.To discuss the reported complaints.At the conclusion of the meeting, it was explained by (b)(6), bidmc clinical engineer, that all issues that were reported to fda on the ufr-mdr were also reported to teleflex in the form of a complaint and that they were satisfied with the response from teleflex and no further action was required from teleflex.
|
This complaint was opened because an mdr/ufr was received by teleflex from fda.The mdr/ufr was submitted to them from beth israel deaconess medical center, which alleged several issues they experienced with iab/iabp devices.No specific dates of the alleged issues, patient involvement information or serial/lot number information was reported.
|